SCHEMBL3707735

SCHEMBL3707735

CC(=O)N(C)c1ccc(Nc2nc(N3CCC(N(C)C(=O)O)CC3)c3occc3n2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.39
MAPT P10636 4/20 0.39
HTT P42858 4/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
SYK P43405 2/20 0.38
LRRK2 Q5S007 1/20 0.37
BRAF P15056 2/20 0.37
ALOX15 P16050 2/20 0.36
MAPK1 P28482 2/20 0.36
HSD17B10 Q99714 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
SOS2 Q07890 1/20 0.36
GAA P10253 2/20 0.36
RAD52 P43351 2/20 0.36
JAK3 P52333 1/20 0.36
BTK Q06187 1/20 0.36
CD69 Q07108 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707733 0.86 LMNA (0.40) LMNAMAPTHTTALDH1A1SMN1; SMN2
SCHEMBL3704407 0.86 SYK (0.40) LMNAMAPTHTTALDH1A1SMN1; SMN2
SCHEMBL3710081 0.85 JAK3 (0.44) SYKJAK3BTKCD69
SCHEMBL3706179 0.85 PIK3R1 (0.43) LRRK2
SCHEMBL3700449 0.84 ALDH1A1 (0.41) LMNAMAPTHTTALDH1A1SMN1; SMN2
SCHEMBL3702526 0.82 HTT (0.36) LMNAMAPTHTTALDH1A1SMN1; SMN2
SCHEMBL3707445 0.82 TRPV1 (0.40) SYKLRRK2BRAFJAK3BTK
SCHEMBL3702655 0.82 LMNA (0.38) LMNAMAPTHTTALDH1A1SMN1; SMN2
SCHEMBL3712744 0.81 SYK (0.37) MAPTALDH1A1SYKHPGDJAK3
SCHEMBL3711314 0.80 JAK2 (0.53) LMNAMAPTHTTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 LMNA 2043/4885MAPT 2194/4885HTT 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.